ZYUS Life Sciences announces positive topline results from the Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe cancer-related pain.
bit.ly/4hjmI
#ZYUS #NonOpioid #PainManagement #Cancer
3
28
#ZYUS that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 trial evaluating efficacy of Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.
zyus.com/2026-04-16-ZYUS-Lif…
#ClinicalTrials #Oncology
1
14
ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement
zyus.com/2026-02-24-ZYUS-Lif…
17
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
bit.ly/4jDmHYm
#ZYUS #clinicalresearch #Lifesciences
21
ZYUS (TSXV: ZYUS) today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.
bit.ly/3LDo7Fz
#LifeSciences #ClinicalTrials
24
#ZYUS Life Sciences Corp announced a key milestone in its ongoing Phase 2a UTOPIA-1 trial, with patient enrollment reaching 25%.
zyus.com/news-and-events/new…
#ClinicalTrials #Oncology #Innovation #NonOpioid #ZYUSLifeSciences #PainManagement #ZYUS #CancerResearch
31
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment
#ZYUS #TSXVZYUS #InvestorNews #LifeSciences
zyus.com/news-and-events/new…
28
ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note
zyus.com/news-and-events/new…
#ZYUS #LifeSciences #Biotech #ClinicalResearch #CannabinoidScience #PainManagement
18
Milestone for #ZYUS announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 cancer pain trial. Now 3 active sites enrolling patients across Canada.
zyus.com/news-and-events/new… #cancerpain #Clinicaltrial #TSXV #LifeSciences
31
#ZYUS announces activation of Centre Hospitalier de l'Université de Montréal as the first site in its Phase 2a UTOPIA-1 trial for cancer pain.
Advancing non-opioid innovation.
bit.ly/4fUstCN
#ClinicalTrial #Oncology #PainManagement #Biotech #CancerResearch
40
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
bit.ly/3FjC6xb
#ZYUS #Phase2Trial #Cannabinoids #InnovativeMedicine #OncologyResearch #PainManagement #ClinicalTrial #PressRelease #LifeSciences #Biotechnews
34
#ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
bit.ly/3xG7ba3
#PressRelease #ExcitingNews #Innovation #LifeSciences #PatentIssuance #InnovationInHealthcare #NonOpioidPainManagement #MedicalInnovation #PatientOutcomes #US
ZYUS is pleased to announce receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human Clinical Trial for its lead drug product candidate, Trichomylin® softgels. #ZYUS #HealthcareInnovation #CannabinoidTherapies #ChronicPain
1
78
📣 Exciting news from ZYUS Life Sciences Corp
zyus.com/news-and-events/new…
#zyus #PressRelease #news #lifesciences #Innovation – at Saskatoon, Saskatchewan
59
ZYUS Life Sciences Corp retweeted
Brent Zettl, President & CEO, @ZYUSCorp (TSXV:ZYUS), and his team joined us to close the market and celebrate the Company’s listing on TSX Venture Exchange.
$ZYUS is a Canadian life sciences company committed to reinventing the treatment of chronic and neuropathic pain by harnessing the therapeutic properties of cannabinoid formulations.
#ZYUS is pleased to welcome renowned business leader, Wayne Brownlee to ZYUS’ Board of Directors. #ZYUS #BusinessNews #PressRelease #TSXV #clinicalresearch – at Saskatoon, Saskatchewan
2
58
#ZYUS commenced trading today on the TSX Venture Exchange (#tsxv), under the ticker symbol “ZYUS”.
.
.
.
#businessnews #canadiannews #lifesciences #stockmarket #stockexchange #trading – at Saskatoon, Saskatchewan
2
164
#ZYUS Life Sciences Corporation (the “Company”) has been approved by the TSX Venture Exchange (“TSX-V”) to commence trading on Monday, June 19, 2023, under the ticker symbol “ZYUS”. #TSXV
bit.ly/46bWoBt
1
77
ZYUS Life Sciences Corporation Announces Completion of RTO #zyus #Biotechnology #RTO #PressRelease #CanadaNewsToday #lifesciences #clinicalresearch
bit.ly/45WFCWJ – at Saskatoon, Saskatchewan
2
71



















